News
HIV, CVS Health and Gilead
Digest more
CVS Health will not add Gilead Sciences' new HIV prevention drug to its commercial plans for now, despite the medicine's ...
A source familiar with the situation suggested that Gilead is still negotiating with CVS over Yeztugo, a twice-yearly injection with a U.S. list price of more than $28,000 a year.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback